Jazz Pharmaceuticals has agreed to buy Celator Pharmaceuticals, which makes a treatment for a type of leukemia, for $1.5 billion. The treatment is called Vyxeos and is being touted as the first product candidate to demonstrate a statistically significant improvement in overall survival in patients with acute myeloid leukemia (AML). U.S. FDA breakthrough therapy designation has been granted for Vyxeos. It has also received orphan drug status from both U.S. FDA and European Commission for the t...